期刊文献+

可比特雾化吸入治疗慢性阻塞性肺病疗效观察及护理

Study on Effect of Kebite Jet Nebulizer Inhalation on COPD and Nursing
下载PDF
导出
摘要 目的观察可比特雾化吸入剂对慢性阻塞性肺病的治疗作用。方法将50例病人随机分为2组。对照组应用抗炎、祛痰、平喘治疗;治疗组在对照组的基础上加用可比特雾化剂雾化吸入5~7天,治疗前与治疗后分别观察肺功能与显效率。结果两组治疗5~7天后,治疗组的显效率、有效率明显高于对照组,差异有显著性(P<0.05)。治疗组:肺功能指标FEV1由治疗前的1.0±0.51到治疗后的1.47±0.60,PEF由治疗前的2.9±1.01到治疗后的4.32±1.08,差异有高度显著性(P<0. 01),而对照功能指标FEV1由治疗前的1.03±0.28到治疗后的1.22±0.3,PEF由治疗前的3.03±1.10到治疗后的3.75±1. 20,差异有显著性(P<0.05),两组间肺功能指标比较治疗组明显优于对照组(P<0.05)。结论可比特雾化剂客化吸入提高慢性阻塞性肺病的疗效,改善病人的肺功能。 Objective To study the effect of Kebite jet nebulizer inhalation on COPD. Methods 50 cases were randomly divided into two groups. The control group was given anti inflammatory therapy and pectoral and antiasthmoid treatment. While the treatment group was given kebite jet nebulizer inhalation additionally for 5 - 7 days on the basis of the control group, observing the pulmonary functions and the regreession rate. Results After 5 - 7 days treatment, the regression rate and effective rate of the treatment group were much higher than that of the control group( P 〈 0.05). For the treatment group, the pulmonary function index FEV1 changed from 1. 0 ± 0.51 before the treatment to 1.47 ± 0.60 after the treatment, PEF from 2.9 ± 1.01 to 4.32 ± 1.08. There was significant difference (P〈0.01). However, in the control group, the pulmonary function index FEV1 changed from 1.03 ± 0.28 before the treatment to 1.22 ± 0.3 after the treatment, PEF from 3.03 ± 1.10 to 3.75 ±1.20, there was difference (P〈0.05). The treatment group was much better than that of the control group in the pulmonary function index (P〈0.05). Conclusion Kebite jet nebulizer inhalation can improve the effect of COPD and the patients' pulmonary function.
作者 陈静
出处 《菏泽医学专科学校学报》 2005年第4期74-76,共3页 Journal of Heze Medical College
关键词 可比特/治疗应用 雾化吸入/投药和剂量 慢性阻塞性肺病/治疗 肺功能 护理 Kebite/therapeutic use jet nebulizer inhalation/administration and dosage COPD/therapy pulmonary function nursing
  • 相关文献

参考文献4

二级参考文献11

  • 1Mahlfr DA. The effect of inhaled beta 2 - agonists on clinical outcomes in chronic obstructive pulmonary disease. Journal of Allergy & Clinical Immunology,2002,110(6 Suppl): s298 - s303.
  • 2Dimarco F, Milic- Emili J, Boveri B, et al. Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD. European Respiratory Journal,2003,21 (1) :86 - 94.
  • 3Levin DC,Little KS,Laughlkn KR, et al. Addition of anticholinergic solution prolongs bronchodilator effect of beta 2 agonists in patients with chronic obstructive pulmonary disease. American Joumal of Medicine,1996,100(1A): s40 - s48.
  • 4Dorinsky PM, Reisner C, Ferguson GT, et al. The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD. Chest, 1999,115(4): 966 - 971.
  • 5Friedman M,Serby CW, Menjoge SS,et al. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest, 1999,115(3):635- 641.
  • 6Oga T, Nishimura K, Tsukino M, et al. A comparison of the effects of salbutamol and ipratropium bromide on exercise endurance in patients with COPD. Chest,2003,123(6):1 810-1 816.
  • 7林耀广.呼吸内科诊疗常规[M].北京:人民卫生出版社,2003.314-325.
  • 8Bosley CM,Parry DT,Cochrane GM.Patient compliance with inhaled medcation:dose combining beta-agonists with corticosteroids improve compliance?[J].Eur Respir J,1994,7:504
  • 9Myrna B,Dean R,Paula Anderson,et al.Device selection and outcomes of aerosol therapy:evidence-based guidelines[J].Chest,2005,127:335-371
  • 10季蓉,何权瀛.25例住院哮喘患者应用必可酮气雾剂的依从性调查报告[J].北京医学,1999,21(2):114-115. 被引量:7

共引文献1396

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部